Canine (Canis lupus familiaris) Research Reagents

Anticorps et protéines recombinantes Canine (Canis lupus familiaris) — réactifs validés pour la recherche. abinScience.

Pourquoi les chercheurs choisissent abinScience

Validation spécifique à l'espèce Antibodies validated with confirmed reactivity to your model organism using appropriate positive controls.

Large couverture des cibles Immune markers, signaling molecules, structural proteins, and disease-relevant biomarkers.

Données de réactivité croisée Detailed species cross-reactivity information provided on every product datasheet.

Applications multiples Validated for WB, IHC, IF, ELISA, and FC across veterinary, developmental, and comparative biology research.

Fabricant d'origine In-house production with rigorous quality control — reliable supply and consistent quality.

Documents & données QC

Download product datasheets, images de validation (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQ

Comment vos anticorps sont-ils validés ?

Every antibody is validated in its listed applications (WB, IHC, IF, ELISA, FC) with supporting images and data on the product page. We use positive and negative controls plus knockout/knockdown verification where available.

Proposez-vous des anticorps conjugués ?

Yes — HRP, AP, biotin, FITC, PE, APC, Alexa Fluor, and other fluorochrome conjugates are available. Custom conjugation services are also offered for bulk orders.

Avec quelles espèces vos anticorps réagissent-ils ?

Most antibodies target human, mouse, and rat. Many show validated cross-reactivity with additional species. Check the product datasheet for confirmed reactivity data.

Quelle est votre politique de remplacement ?

If a product does not perform as described under recommended conditions, contact us within 30 days for replacement or credit. Our technical team will help troubleshoot first.

Puis-je obtenir des anticorps personnalisés ?

Yes — our parent company AtaGenix offers full custom antibody development from immunogen design through hybridoma screening and scale-up production.